Compare
Cytek Biosciences, Inc. vs Seer, Inc. vs Bio-Rad Laboratories, Inc. vs Revvity, Inc.
| Latest fiscal year | Cytek Biosciences, Inc. CTKB | Seer, Inc. SEER | Bio-Rad Laboratories, Inc. BIO | Revvity, Inc. RVTY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-28 |
| Revenue | $201.49M | $16.58M | $2.58B | $2.86B |
| Revenue growth (YoY) | +0.5% | +17.0% | +0.7% | +3.7% |
| Gross margin | 51.8% | 51.1% | 51.9% | n/a |
| Operating margin | -20.0% | -470.5% | 1.8% | 12.5% |
| Net margin | -33.0% | -444.0% | 29.4% | 8.4% |
| Net income | -$66.54M | -$73.60M | $759.90M | $241.20M |
| EPS (Diluted) | n/a | n/a | $27.85 | $2.07 |
| Operating cash flow | -$4.69M | -$44.45M | $532.20M | $582.93M |
| Free cash flow | -$8.77M | -$46.24M | $374.60M | $509.41M |
| Cash & equivalents | $90.85M | $47.28M | $529.80M | $919.86M |
| Total assets | $461.54M | $296.08M | $10.58B | $12.17B |
| Total liabilities | $119.80M | $36.78M | $3.12B | $4.92B |
| Shareholders' equity | $341.74M | $259.31M | $7.45B | $7.25B |
| Return on year-end equity | -19.5% | -28.4% | 10.2% | 3.3% |
| Shares outstanding | 128.55M | n/a | n/a | 112.28M |
Revenue, most recent five fiscal years
| Fiscal year | Cytek Biosciences, Inc. | Seer, Inc. | Bio-Rad Laboratories, Inc. | Revvity, Inc. |
|---|---|---|---|---|
| Latest | $201.49M Ended 2025-12-31 | $16.58M Ended 2025-12-31 | $2.58B Ended 2025-12-31 | $2.86B Ended 2025-12-28 |
| 1 year earlier | $200.45M Ended 2024-12-31 | $14.17M Ended 2024-12-31 | $2.57B Ended 2024-12-31 | $2.76B Ended 2024-12-29 |
| 2 years earlier | $193.01M Ended 2023-12-31 | $16.66M Ended 2023-12-31 | $2.67B Ended 2023-12-31 | $2.75B Ended 2023-12-31 |
| 3 years earlier | $164.04M Ended 2022-12-31 | $15.49M Ended 2022-12-31 | $2.80B Ended 2022-12-31 | $3.31B Ended 2023-01-01 |
| 4 years earlier | $127.95M Ended 2021-12-31 | $6.62M Ended 2021-12-31 | $2.92B Ended 2021-12-31 | $3.83B Ended 2022-01-02 |